The molecular diagnostics and experimental therapeutics research program has a broad research focus on understanding the molecular pathogenesis of human gastrointestinal cancers and its relationship to early detection of cancer, cancer prevention and cancer therapeutics.
More specifically, the major objective of our research involves deciphering the interplay between genetic and epigenetic alterations in sporadic and familial (e.g., Lynch syndrome, familial adenomatous polyposis, serrated polyposis) forms of colorectal cancer and other gastrointestinal cancers (gastric, pancreatic, esophageal and hepatocellular).
  • Conduct high-quality research into the pathogenesis of gastrointestinal cancers
  • Develop clinically useful biomarkers for the early detection of colorectal, pancreatic, gastric and esophageal cancers
  • Develop clinically useful biomarkers that can help direct therapy for gastrointestinal cancers
  • Understand the molecular basis of early-onset and familial colorectal cancer
  • Chemoprevention of colorectal cancer